For the third quarter of the fiscal year ending March 2026, consolidated net sales were \u00a52,363,086 million (4.5% YoY increase), operating income was \u00a529,731 million (4.5% YoY decrease), and net income attributable to owners of parent for the quarter was \u00a531,981 million (24.3% YoY increase).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2784","jir_company_name":"Alfresa Holdings Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-02-10","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/2784-20260210-01.pdf","jir_short_summary":"For the third quarter of the fiscal year ending March 2026, consolidated net sales were \u00a52,363,086 million (4.5% YoY increase), operating income was \u00a529,731 million (4.5% YoY decrease), and net income attributable to owners of parent for the quarter was \u00a531,981 million (24.3% YoY increase).","jir_summary":"### Overview of Financial Results\nIn the third quarter of the fiscal year ending March 2026, net sales increased to \u00a52,363,086 million, up 4.5% year-over-year. Operating income was \u00a529,731 million, down 4.5% year-over-year, and ordinary income was \u00a531,642 million, a 4.6% decrease. Net income attributable to owners of the parent for the quarter significantly increased to \u00a531,981 million, a 24.3% rise year-over-year, mainly due to gains on sales of investment securities from the reduction of policy-held shares. By segment, the pharmaceutical wholesale business for prescription drugs recorded net sales of \u00a52,118,220 million (4.9% increase YoY) and operating income of \u00a527,076 million (1.1% increase YoY), maintaining steady performance. The self-medication wholesale business also achieved both revenue and profit growth, while the pharmaceutical manufacturing business experienced declines in revenue and profit due to drug price revisions and other factors. The dispensing pharmacy business saw a slight increase in net sales but a decrease in operating income.\n\n### Financial Position and Outlook\nTotal assets increased by \u00a5187,008 million from the previous fiscal year-end to \u00a51,626,893 million, and net assets grew by \u00a514,846 million to \u00a5497,094 million. The equity ratio declined to 30.5% from 33.5% at the end of the previous fiscal year. There is no revision to the full-year forecast announced in November 2025, expecting net sales of \u00a53,107,000 million (4.9% increase YoY), operating income of \u00a537,100 million (2.6% decrease YoY), and net income attributable to owners of parent of \u00a536,000 million (31.4% increase YoY). For medium to long-term growth, the company has formulated the '2025-27 Medium-term Management Plan Vision 2032 Stage 2,' focusing on strengthening its business foundation and promoting the CDMO business for biosimilars.","jir_financial_highlights":"Net Sales: 2,363,086 million yen (4.5% YoY increase)\nOperating Income: 29,731 million yen (4.5% YoY decrease)\nOrdinary Income: 31,642 million yen (4.6% YoY decrease)\nNet Income Attributable to Owners of Parent: 31,981 million yen (24.3% YoY increase)\nTotal Assets: 1,626,893 million yen (Increase from previous fiscal year-end)\nNet Assets: 497,094 million yen (Increase from previous fiscal year-end)\nEquity Ratio: 30.5% (Decrease from 33.5% at previous fiscal year-end)\nAnnual Dividend (Forecast): 68.00 yen (Increase from previous fiscal year)","jir_category":"","jir_hashtags":"#AlfresaHoldings, #FinancialSummary, #JapaneseStocks","jir_key_figures":"Net Sales: \u00a52,363,086 million (4.5% YoY increase)\nOperating Income: \u00a529,731 million (4.5% YoY decrease)\nNet Income Attributable to Owners of Parent: \u00a531,981 million (24.3% YoY increase)","jir_meta_title":"Alfresa Holdings FY March 2026 Q3 Financial Results - 4.5% Sales Increase, 24.3% Net Profit Growth","jir_meta_description":"Alfresa Holdings Corporation FY March 2026 Q3 Financial Summary: Net sales of \u00a52,363 billion (4.5% YoY increase), operating income of \u00a529.7 billion (4.5% YoY decrease), and net income attributable to owners of parent of \u00a532.0 billion (24.3% YoY increase).","jir_og_title":"Alfresa Q3 FY March 2026 Earnings Announcement - Sales Increase","jir_og_description":"Consolidated Q3 results for FY March 2026 show net sales increased 4.5% YoY and net profit rose 24.3%.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Sales Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY March 2025 Q3\\\",\\\"FY March 2026 Q3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[2262324,2363086],\\\"backgroundColor\\\":\\\"#4e79a7\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Operating Income Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY March 2025 Q3\\\",\\\"FY March 2026 Q3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[31148,29731],\\\"backgroundColor\\\":\\\"#f28e2b\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Income Attributable to Owners of Parent Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY March 2025 Q3\\\",\\\"FY March 2026 Q3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Quarterly Net Income\\\",\\\"data\\\":[25726,31981],\\\"backgroundColor\\\":\\\"#e15759\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Segment Net Sales Composition (FY March 2026 Q3)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"pie\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Pharmaceutical Wholesale Business\\\",\\\"Self-medication Wholesale Business\\\",\\\"Pharmaceutical Manufacturing Business\\\",\\\"Dispensing Pharmacy Business\\\",\\\"Others\\\"],\\\"datasets\\\":[{\\\"data\\\":[2118220,204341,39486,27888,0],\\\"backgroundColor\\\":[\\\"#4e79a7\\\",\\\"#f28e2b\\\",\\\"#e15759\\\",\\\"#76b7b2\\\",\\\"#59a14f\\\"]}]}}\"}, {\"jir_chart_id\": \"dividend_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Annual Dividend Trend (Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY March 2025\\\",\\\"FY March 2026 (Forecast)\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Annual Dividend\\\",\\\"data\\\":[63.00,68.00],\\\"backgroundColor\\\":\\\"#edc949\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":7908,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-26468","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n